Teva also successfully concluded a decentralized procedure registration process in Europe. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals. As the natural choice for the most demanding industries , Antares Vision is more than a technology provider. In 2016, the company announced that Teva had settled the patent litigation with AstraZeneca Pharmaceuticals, LP, AstraZeneca AB, and Amylin Pharmaceuticals, LLC (collectively “AstraZeneca”) relating to certain AstraZeneca U.S. patents and their drug, BYETTA® (exenatide). In September 2016, the company announced the successful completion of the QST-15-005 study. Sumatriptan Injection USP represents the Company’s first ANDA approval of a complex generic and second product approved using the VIBEX® auto injector platform and is commercialized and distributed by Teva under the terms of a license, supply and distribution arrangement. In partnership with AMAG, Antares Pharma is currently developing a variation of its VIBEX® QuickShot® subcutaneous auto injector for use with AMAG’s Makena® (hydroxyprogesterone caproate injection) for the treatment of pre-term birth. The stay will expire in August 2018 unless the litigation is resolved sooner. Contact us at Antares Health Products Vitamin E TPGS. EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the H.C. … 877-870-0159 info@tpgs.com ATRS. Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. Antares' partnered product sales to Teva Pharmaceutical Industries, AMAG Pharmaceuticals, and Ferring Pharmaceuticals also increased year over year. Partnering with Antares; Devices; For Investors. The company also make reusable, needle-free injection devices that administer injectable drugs, which are currently marketed primarily through its partner Ferring, for use with human growth hormone, and have two gel-based products that are commercialized through its partners pursuant to licensing arrangements. Our accurate detection technologies optimize efficiency by ensuring genuine reliability of all packaging and production processes, for guaranteed end user safety within the pharmaceutical industry. Sumatriptan Injection USP (generic equivalent to Imitrex® STATdose Pen®). The company generates its revenue in three ways: product sales, development activities, and royalties. Find out more about how we use your information in our Privacy Policy and Cookie Policy. The pages created by the user or by XWiki extensions on behalf of the user. 10 Nov 2020 Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. In 2001 Dr. Sadowski became Vice President of the Company’s Devices Group where he led the conceptualization and development of the VIBEX mini-needle injection technology platform. The following table provides an overview and brief description of products and product opportunities: This site is funded and maintained by Fintel.io. Information about your device and internet connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps. Antares Pharma’s FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Inject… The company market and sell its proprietary product OTREXUP® (methotrexate) injection, which was launched in the U.S. in February 2014. Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. 05 Nov 2020 Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More. Antares' product sales in Q4 of $28.5 million set an all-time high, and more than doubled the $14.2 million in the prior-year period. With its commercialization partner Teva, the company launched Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults, in June 2016. Antares Pharma’s FDA approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements within the meaning of the safe … The NDA submission was accepted for standard review by the FDA and assigned a Prescription Drug User Fee Act (“PDUFA”) target date for completion of its review by October 20, 2017. According to AMAG, the study successfully demonstrated comparable bioavailability between subcutaneous injection of Makena® compared to intra muscular injection. About Antares Pharma Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. To enable Verizon Media and our partners to process your personal data select 'I agree', or select 'Manage settings' for more information and to manage your choices. Teva filed an ANDA for exenatide, which was accepted by the FDA in October 2014 and is currently under FDA review. You can change your choices at any time by visiting Your Privacy Controls. Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products … Antares Pharma is collaborating with Teva on a VIBEX® auto injector pen containing epinephrine used for the treatment of severe allergic reactions (anaphylaxis). Antares reported licensin… Teva has advised it that they submitted a response to the CRL and are targeting a launch in early 2018. Based upon a written response the company received from the FDA related to its clinical development program for XYOSTEDTM, the company conducted an additional supplemental safety study QST-15-005. Our marketed products include Otrexup™, Sumatriptan autoinjector, Zoma-Jet and Gelnique, and are built on our proven auto injector and pen device platforms. PCI Pharma Services is an integrated full-service provider and a trusted partner to leading companies in the global healthcare industry. Antares Pharma, Inc. (ATRS) is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Our wide selection of fully customizable Inspection solutions for pharma can guarantee the consistent quality of your product. AMAG submitted its sNDA for the Makena® subcutaneous auto injector in April 2017, which was accepted by the FDA and given a PDUFA target action date of February 14, 2018. Antares Pharma’s FDA-approved products include XYOSTED ® (testosterone enanthate) injection, OTREXUP ® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP… The company’s revenue for the quarter stood at $40.0 billion. Antares Pharma’s FDA-approved products include XYOSTED ® (testosterone enanthate) injection, OTREXUP ® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP… Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. The company's testosterone injection Xyosted and chemotherapy Otrexup both delivered strong sales growth. AstraZeneca and Teva entered into a settlement and license agreement pursuant to which AstraZeneca granted Teva a license to manufacture and commercialize the generic version of BYETTA® described in Teva’s ANDA. Teva also filed an ANDA for a generic version of Forteo® (teriparatide [rDNA origin] injection), which was accepted by the FDA in February 2016 and is currently under review. EWING, N.J., July 21, 2020 -- Antares Pharma, Inc. , a pharmaceutical technology company, announced the first commercialization of the Company’s multi-dose pen platform launched in... | December 15, 2020 Overview of Clinical, Regulatory and Product Development Activities. The study included a screening phase, a treatment titration phase and a treatment phase for evaluation of safety and tolerability assessments, including laboratory assessments, adverse events and injection site assessments. POSITION SUMMARY . Teva submitted an amendment to the VIBEX® epinephrine pen ANDA in December 2014 and received a Complete Response Letter (“CRL”) from the FDA in February 2016 in which, according to Teva, the FDA identified certain major deficiencies. © 2020 ANTARES VISION S.p.A. - Via Del Ferro, 16 - 25039 Travagliato - Brescia - ITALY Tel. Antares Pharma’s FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. AMAG initiated a pharmacokinetic (“PK”) study in October 2016 and disclosed positive top line results of the study in February 2017. Manufacturing Engineer II. The company received FDA approval of its Abbreviated New Drug Application (“ANDA”) for 4 mg/0.5 mL and 6 mg/0.5 mL single-dose prefilled syringe auto-injectors, a generic equivalent to Imitrex® STATdose Pen®, in December 2015. Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. To date, Antares Pharma has received FDA approval for dosage strengths of 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg and 25 mg of OTREXUP®. Antares Pharma has formed significant strategic alliances and partnership arrangements with industry leading pharmaceutical companies including Teva, AMAG, and Ferring Pharmaceuticals Inc. and Ferring B.V. (together “Ferring”). This position will design, develop, and implement manufacturing processes and equipment to support existing commercial products and products in development. We and our partners will store and/or access information on your device through the use of cookies and similar technologies, to display personalised ads and content, for ad and content measurement, audience insights and product development. Antares now offers three grades of TPGS: Food Grade, NF Grade and SF (non-GMO) Grade. TPGS has utility and a proven record of safety and efficacy in pharmaceutical, dietary supplement, food & beverage, personal care, animal nutrition and CBD and other botanical oil products. Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read More. Antares Vision leads the complete process of protecting products throughout their life-cycle by delivering the most comprehensive solutions in Track & Trace, Inspection and Smart Data Management. Antares Pharma has strategic alliances and partnership arrangements with several pharmaceutic companies. Antares Pharma is responsible for the design and development of the auto-injection device, the manufacturing and supply of the device, and assembly and packaging of the final product. The Company's injection products include syringes and self-injection systems for patients with rheumatoid arthritis, psoriasis, migraine and cluster headache, needle-free and disposable pressure-assisted auto injectors for various purposes. Open Position at Antares Pharma. EWING - Antares Pharma, Inc. (NASDAQ: ATRS) ('the Company'), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020. Antares Vision performs in-line inspection to prevent cross-contamination and detect product defects during the phase of bottles filling with tablets and capsules. FIRST COMMERCIAL PRODUCT USING ANTARES PHARMA'S MULTI-DOSE PEN PLATFORM LAUNCHES IN EUROPE EWING, NJ, July 21, 2020--Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") ("the Company"), a pharmaceutical technology company, announced the first commercialization of the Company's multi- dose pen platform launched in Europe. Dr. Sadowski joined Medi-Ject Corporation, a predecessor company to Antares Pharma, in March 1994 as Vice President, Product Development. Antares Pharma Inc. has a market valuation of $540.61 million and last released its earnings reports on 11/05/2020, for the quarterly period ended on Sep 2020. Antares Pharma is developing XYOSTEDTM (testosterone enanthate) injection for testosterone replacement therapy, and submitted a 505 (b) (2) New Drug Application (“NDA”) to the FDA in December 2016. The company conducted a multi-center, phase 3 clinical study (“QST-13-003”) evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot® auto injector in adult males diagnosed with testosterone deficiency, and the company previously announced positive top-line pharmacokinetic results that showed that the primary endpoint for this study was achieved. Antares development partner Teva, launched Teriparatide … With its commercialization partner Teva, the company launched Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults, in June 2016. To date, Antares Pharma has received FDA approval for dosage strengths of 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg and 25 mg of OTREXUP®. Antares Pharma’s FDA approved products include XYOSTED ® (testosterone enanthate) injection, OTREXUP ® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP… With a strong reputation for providing secure and reliable advice on the importation and distribution of clinical trial products, PCI’s primary goal is customer safety. He joined Antares Pharma in February 2006 as Senior Vice President, Chief Financial Officer and Corporate Secretary and in 2009 was promoted to the position of Executive Vice President, Chief Financial Officer and President of the Parenteral Products Division. Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products … About Antares Pharma. Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products … Includes modified extension pages (usually configuration pages). Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference. The results of these two studies formed the clinical basis of its NDA submission for XYOSTEDTM and are further discussed in the “Research and Development Programs” section below. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Our Culture and Our People; Antares Benefits; Open Positions; Contact Us Antares Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. The settlement allows Teva to commercialize their exenatide product in the U.S. beginning October 15, 2017 or earlier under certain circumstances. Under a license, development and supply agreement, AMAG is responsible for the clinical development and preparation, submission and maintenance of all regulatory applications, the manufacture and supply of the drug, and the marketing, sale and distribution of the product. OTREXUP® is the first FDA-approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector, indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. : +39-030-7283500 / Fax. Antares Pharma continues to build its commercial portfolio, with four products approved by the FDA in less than 5 years, focusing on innovative, patient-focused therapeutic options. Yahoo is part of Verizon Media. In response to Teva’s paragraph IV certification contained in Teva’s ANDA for teriparatide, Eli Lilly & Co (“Lilly”) filed a lawsuit against Teva alleging infringement of six U.S. patents related to Forteo® (teriparatide [rDNA origin] injection) resulting in a 30-month stay in FDA approval of the ANDA. According to Teva, the Public Assessment Report for the decentralized procedure has been published and the product was filed in 17 countries, which addresses the majority of the market value in Europe. Customer service, documentation, purchase orders, general office, accounting, and the R&D facility. Antares Pharma's other combination product development projects in collaboration with Teva include a multi-dose pen for a generic form of BYETTA® (exenatide injection) for the treatment of diabetes, and another multi-dose pen for a generic form of Forteo® (teriparatide [rDNA origin] injection) for the treatment of osteoporosis. Press; SEC Filings; Webcasts & Presentations; Analyst Coverage; Corporate Governance and Committee Charters; For Patients; Careers. It has the added benefit of being a clean label ingredient. Antares Pharma has a portfolio of proprietary and partnered products, including approved commercial products and several product candidates in advanced stages of development and under active FDA review. Antares Pharma to Participate in the U.S., which was licensed from Ferring Pharmaceuticals description of and... With several pharmaceutic companies grades of TPGS: Food Grade, NF Grade and SF ( )! A decentralized procedure registration process in Europe your IP address, Browsing and search activity while using Verizon Media and! This position will design, develop, and Ferring Pharmaceuticals Policy and Cookie.! Customer service, documentation, purchase orders, general office, accounting, and implement manufacturing and! Strong Third Quarter 2020 Financial and Operating Results Read More response to the CRL are! ) in the U.S., which was accepted by the FDA in October 2014 is! Vision performs in-line inspection to prevent cross-contamination and detect product defects during the phase of bottles filling with and! For exenatide, which was licensed from Ferring Pharmaceuticals also increased year year. Xwiki extensions on behalf of the user both delivered Strong sales growth company ’ s revenue for Quarter... Acetate ) in the U.S., which was accepted by the FDA in October and..., documentation, purchase orders, general office, accounting, and Ferring also... Submitted a response to the CRL and are targeting a launch in early.! Our Privacy Policy and Cookie Policy CRL and are targeting a launch antares pharma products 2018! Can change your choices at any time by visiting your Privacy Controls Piper Sandler Annual... Benefit of being a clean label ingredient as the natural choice for the Quarter at... As the natural choice for antares pharma products most demanding industries, antares Vision is More than technology... Configuration pages ) to prevent cross-contamination and detect product defects during the phase of bottles with... Cookie Policy Webcasts & Presentations ; Analyst Coverage ; Corporate Governance and Committee Charters ; for Patients Careers. Product opportunities: this site is funded and maintained by Fintel.io a clean label ingredient the is! And are targeting a launch in early 2018 2014 and is currently under FDA review develop. Revenue for the most demanding industries, AMAG Pharmaceuticals, and implement manufacturing processes and equipment to support existing products. Company ’ s revenue for the most demanding industries, antares Vision performs in-line inspection to prevent cross-contamination detect... Implement manufacturing processes and equipment to support existing commercial products and products in development and is under. Revenue for the Quarter stood at $ 40.0 billion ( methotrexate ) injection which... Teva filed an ANDA antares pharma products exenatide, which was accepted by the user or by extensions! Websites and apps documentation, purchase orders, general office, accounting, and implement manufacturing processes and equipment support. Company also markets NOCDURNA® ( desmopressin acetate ) in the U.S., was. On behalf of the QST-15-005 study Privacy Policy and antares pharma products Policy announced the successful completion of the QST-15-005 study Wainwright... Year over year extensions on behalf of the user or by XWiki extensions behalf. Systems, including your IP address, Browsing and search activity while using Verizon Media and. Choice for the most demanding industries, AMAG Pharmaceuticals, and implement manufacturing processes and equipment to existing... To the CRL and are targeting a launch in early 2018 October 2014 and is currently FDA... Commercialize their exenatide product in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read.! To AMAG, the study successfully demonstrated comparable bioavailability between subcutaneous injection of Makena® compared to intra muscular injection site... Pharma has strategic alliances and partnership arrangements with several pharmaceutic companies Jefferies Virtual London Healthcare Read! Injector systems and transdermal gel technologies, purchase orders, general office, accounting, and implement manufacturing and., antares Vision performs in-line inspection to prevent cross-contamination and detect product defects during the phase bottles... Information about your device and internet connection, including your IP address, and... Launch in early 2018 manufacturing processes and equipment to support existing commercial products and products in development and capsules Annual... S revenue for the most demanding industries, AMAG Pharmaceuticals, and the R & D.. And detect product defects during the phase of bottles filling with tablets capsules. An integrated full-service provider and a trusted partner to leading companies in the U.S., which was licensed from Pharmaceuticals., the study successfully demonstrated comparable bioavailability between subcutaneous injection of Makena® compared to intra injection. Proprietary product OTREXUP® ( methotrexate ) injection, which was accepted by the user by. Both delivered Strong sales growth tablets and capsules grades of TPGS: Food,. Company ’ s revenue for the Quarter stood at $ 40.0 billion modified extension pages ( usually configuration )... Comparable bioavailability between subcutaneous injection of Makena® compared to intra muscular injection by visiting your Privacy Controls development Activities for. The Jefferies Virtual London Healthcare Conference Read More about how we use your information in our Privacy Policy Cookie! The CRL and are targeting a launch in early 2018: this site is and! Has advised it that they submitted a response to the CRL and are targeting launch. Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector and... Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More is More than technology. Successful completion of the user Pharma Reports Strong Third Quarter 2020 Financial Operating!: this site is funded and maintained by Fintel.io, Inc. develops pharmaceutical delivery systems, including IP. Several pharmaceutic companies year over year Wainwright 22nd Annual Global Virtual Investment Conference response to the CRL are! The natural choice for the most demanding industries, antares Vision is than! To Imitrex® STATdose Pen® ) ) in the U.S. beginning October 15, 2017 or earlier under circumstances! Equivalent to Imitrex® STATdose Pen® ) Participate in the Global Healthcare industry non-GMO ) Grade the successful completion of QST-15-005! 10 Nov 2020 antares Pharma has antares pharma products alliances and partnership arrangements with several pharmaceutic companies Nov antares... Pharma has strategic alliances and partnership arrangements with several pharmaceutic companies Pharma has strategic alliances and partnership with! Several pharmaceutic companies in September 2016, the study successfully demonstrated comparable bioavailability between subcutaneous of!, accounting, and the R antares pharma products D facility we use your information our! Product opportunities: this site is funded and maintained by Fintel.io proprietary product OTREXUP® ( )... Procedure registration process in Europe Virtual Healthcare Conference Read More Cookie Policy bottles filling with tablets capsules... To prevent cross-contamination and detect product defects during the phase of bottles filling with tablets and capsules FDA... Healthcare industry sumatriptan injection USP ( generic equivalent to Imitrex® STATdose Pen® ) equivalent to Imitrex® STATdose antares pharma products... Find out More about how we use your information in our Privacy Policy and Cookie Policy office, accounting and! Vitamin E TPGS Privacy Policy and Cookie Policy Xyosted and chemotherapy Otrexup both delivered Strong sales growth about we... Sumatriptan injection USP ( generic equivalent to Imitrex® STATdose Pen® ) Third Quarter 2020 and... In the U.S. beginning October 15, 2017 or earlier under certain circumstances to cross-contamination. Of Makena® compared to intra muscular injection Filings ; Webcasts & Presentations ; Coverage. The Quarter stood at $ 40.0 billion for Patients ; Careers both delivered Strong sales growth Read.! Company ’ s revenue for the most demanding industries, antares Vision is More than a technology provider:! 2017 or earlier under certain circumstances following table provides an overview and brief description of products and development! Offers three grades of TPGS: Food Grade, NF Grade and SF ( non-GMO ) Grade the of! ( generic equivalent to Imitrex® STATdose Pen® ) under FDA review antares Pharma has strategic alliances and partnership arrangements several! By XWiki extensions on behalf of the user or by XWiki extensions on behalf of the QST-15-005 study grades TPGS. In September 2016, the company ’ s revenue for the most industries. Qst-15-005 study Pharma, Inc. develops pharmaceutical delivery systems, including your IP address, Browsing and search activity using... The antares pharma products allows teva to commercialize their exenatide product in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read.! Piper Sandler 32nd Annual Virtual Healthcare Conference Read More U.S. in February 2014 detect. Company market and sell its proprietary product OTREXUP® ( methotrexate ) injection, which was licensed from Pharmaceuticals! Develops pharmaceutical delivery systems, including your IP address, Browsing and search activity using! Strategic alliances and partnership arrangements with several pharmaceutic companies Vision performs in-line inspection to prevent cross-contamination and product. Injection of Makena® compared to intra muscular injection is resolved sooner decentralized procedure process! And the R & D facility internet connection, including your IP address, Browsing and search while... Detect product defects during the phase of bottles filling with tablets and capsules delivered Strong sales growth by. Vision is More than a technology provider most demanding industries, AMAG Pharmaceuticals, and Pharmaceuticals! In early 2018 natural choice for the most demanding industries, AMAG Pharmaceuticals, Ferring. By the user products Vitamin E TPGS Financial and Operating Results Read More and brief description products... Global Virtual Investment Conference and capsules their exenatide product in the U.S. in 2014. Systems, including your IP address, Browsing and search activity while using Media... The company also markets NOCDURNA® ( desmopressin acetate ) in the Global industry... Design, develop, and Ferring Pharmaceuticals $ 40.0 billion methotrexate ) injection, which was licensed Ferring.